文章：

靶向MDM2-p53相互作用：Siremadlin治疗TP53野生型慢性淋巴细胞白血病的潜在治疗策略

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for TreatingTP53Wild-Type Chronic Lymphocytic Leukemia

原文发布日期：16 January 2025

DOI: 10.3390/cancers17020274

类型: Article

开放获取: 是

英文摘要：

Background:Chronic lymphocytic leukemia (CLL) treatment has transitioned from traditional chemotherapy to more targeted therapies, but challenges such as resistance and suboptimal responses persist. This study aimed to evaluate HDM201, a second-generation MDM2-p53 binding antagonist, as a novel therapeutic strategy for CLL, with a focus on its effectiveness across differentTP53genetic contexts.Methods:We utilized a panel of B cell leukemia-derived cell lines with varyingTP53statuses, includingTP53-knockout (KO) derivatives of the human B cell line Nalm-6, and assessed the impact of HDM201 on primary CLL samples with bothTP53wild-type and mutant backgrounds.Results:Our results revealed thatTP53wild-type and heterozygousTP53-KO Nalm-6 cells were sensitive to HDM201, whereas homozygousTP53-KO cells and B cells withTP53mutations exhibited significant resistance. Resistance was also noted in primary CLL samples withTP53mutations. HDM201 effectively stabilized p53 and induced apoptosis inTP53wild-type cells but had limited efficacy inTP53mutant cells.Conclusions:These findings indicate that HDM201 holds promise as an additional targeted therapy option for wild-typeTP53CLL. The results underline the importance ofTP53status in predicting treatment efficacy and highlight the potential of HDM201 as a valuable addition to explore in CLL therapy. Future research should focus on identifying additional biomarkers of response and exploring the optimal way to include HDM201 in combination therapies to improve treatment outcomes in CLL.

摘要翻译： 

背景：慢性淋巴细胞白血病（CLL）的治疗已从传统化疗转向更具靶向性的疗法，但耐药性和疗效不足等挑战依然存在。本研究旨在评估第二代MDM2-p53结合拮抗剂HDM201作为CLL新型治疗策略的潜力，重点关注其在不同TP53遗传背景下的有效性。 方法：我们利用一组具有不同TP53状态的B细胞白血病衍生细胞系（包括人B细胞系Nalm-6的TP53敲除衍生株），并评估了HDM201对TP53野生型与突变型原代CLL样本的影响。 结果：研究显示，TP53野生型及杂合性TP53敲除的Nalm-6细胞对HDM201敏感，而纯合性TP53敲除细胞及携带TP53突变的B细胞则表现出显著耐药性。在TP53突变的原代CLL样本中也观察到耐药现象。HDM201能有效稳定TP53野生型细胞中的p53蛋白并诱导细胞凋亡，但对TP53突变细胞的疗效有限。 结论：这些发现表明，HDM201有望成为野生型TP53 CLL的补充靶向治疗选择。研究结果强调了TP53状态在预测疗效中的重要性，并凸显了HDM201作为CLL治疗探索中具有价值的补充方案的潜力。未来研究应聚焦于识别更多疗效相关生物标志物，并探索将HDM201纳入联合治疗方案的最佳策略，以改善CLL的治疗效果。

原文链接：

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for TreatingTP53Wild-Type Chronic Lymphocytic Leukemia